| 前收市價 | 102.00 |
| 開市 | 102.37 |
| 買盤 | 101.29 x 400 |
| 賣出價 | 101.44 x 400 |
| 今日波幅 | 100.45 - 103.79 |
| 52 週波幅 | 62.55 - 142.82 |
| 成交量 | |
| 平均成交量 | 3,775,035 |
| 市值 | 38.828B |
| Beta 值 (5 年，每月) | 1.59 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -12.33 |
| 業績公佈日 | 2024年5月02日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 132.36 |
Investor's Business DailyAnalysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Moderna stock is under pressure and estimates have come down for its first quarter. Is MRNA stock now a sell?
- Reuters
FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
ZacksModerna (MRNA) Stock Moves -0.34%: What You Should Know
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.
